Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response to intradermally administered IXIARO in healthy adults
2024-519876-17-00Phase 4Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Helsinki University Hospital. Primary endpoint: Neutralizing serum antibody levels (PRNT). Planned start Jan 2025; status: authorised.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on 2024-519876-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519876-17-00.